• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Factors Impacting Use of HER2 Therapies for NSCLC

Opinion
Video

Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.

Related Videos
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
5 Experts are featured in this series.
5 Experts are featured in this series.
5 experts in this video
2 experts in this video
5 experts in this video
2 experts in this video
Screenshot of an interview with Kristina Crothers, MD
4 experts are featured in this series
4 experts are featured in this series
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.